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ABSTRACT
The identification of a constantly increasing number
of genes whose mutations are causally implicated in
tumor initiation and progression (cancer genes)
requires the development of tools to store and
analyze them. The Network of Cancer Genes (NCG
3.0) collects information on 1494 cancer genes that
have been found mutated in 16 different cancer
types. These genes were collected from the
Cancer Gene Census as well as from 18 whole
exome and 11 whole-genome screenings of cancer
samples. For each cancer gene, NCG 3.0 provides a
summary of the gene features and the cross-
reference to other databases. In addition, it de-
scribes duplicability, evolutionary origin, orthology,
network properties, interaction partners, microRNA
regulation and functional roles of cancer genes
and of all genes that are related to them. This
integrated network of information can be used to
better characterize cancer genes in the context
of the system in which they act. The data can
also be used to identify novel candidates that
share the same properties of known cancer genes
and may therefore play a similar role in cancer. NCG
3.0 is freely available at http://bio.ifom-ieo-campus.
it/ncg.
INTRODUCTION
The pivotal role of genomic instability in causing human
cancer is an old concept that dates back to the ﬁrst cyto-
genetic studies on cancer cells (1,2). Until very recently,
however, the number of genes whose somatic mutations
are causally implicated in cancer initiation and progres-
sion was very low. This was mainly due to the difﬁcult and
lengthy process of identifying genetic modiﬁcations
through traditional sequencing methods. The recent
development of next-generation sequencing techniques
has boosted the discovery of novel cancer genes. In the
last 5 years, high-throughput mutational screenings were
performed on several cancer types and led to the identiﬁ-
cation of mutations in both coding and non-coding
regions of the cancer genome. So far, around 30
high-throughput and whole genome sequencing experi-
ments on cancer samples have been published, which
identiﬁed around 1500 mutated genes that are potentially
actively involved in cancer development (3–30). This
constant delivery of new sequencing data is radically
changing our understanding of cancer genetics, showing
that the genomic landscape of cancer is complex and
varies among and within cancer types (31). One way to
reduce the complexity implies the identiﬁcation of
properties that are shared among cancer genes and distin-
guish them from the rest of human genes (32). For
example, cancer genes tend to be singletons, i.e. they
preserve one gene copy in the genome, and to encode
hubs, i.e. proteins that engage numerous physical connec-
tions with other proteins (33). Moreover, recessive cancer
genes appeared early in evolution and are involved in basic
cellular processes, while oncogenes originated later and
mainly act as regulators and signal transducers (34).
Thus, the identiﬁcation of speciﬁc properties of cancer
genes may help in better rationalizing their role in
cancer. While several databases collect mutational and
functional information on cancer genes, no description
of their systems-level properties is currently available.
The Network of Cancer Genes (NCG) was originally
created to collect information on duplicability and
network properties of cancer genes (35).
Information on duplicability and network properties of
cancer genes (35). In the current version of the database
(NCG 3.0), we included 1494 cancer genes that have been
identiﬁed so far, and provide an update of the human gene
set and the protein interactome. We also added novel
features, such as the functional description of cancer
genes as well as information about their interaction with
microRNAs (miRNAs). Finally, we developed a new web
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database. Since properties of cancer genes can be also
exploited to identify new candidates that may be
involved in cancer (36), we present a case study that
involves two paralogs, the DNA methyltransferase
alpha (DNMT3A) and beta (DNMT3B). On the basis
of the information that can be retrieved in NCG 3.0,
we hypothesize that, upon the acquisition of somatic mu-
tations, these genes may play an active role in cancer
development.
UPDATES OF DATA SOURCES
Cancer genes
NCG 3.0 includes information on 1494 cancer genes that
were extracted from 30 distinct studies (Table 1). The
genes were divided into three groups, according to the
experimental evidence that supported their involvement
in cancer. The ﬁrst group includes 498 genes from the
latest release of the Cancer Gene Census (CGC, 444
genes, 31 March 2011) (37) and from the census of
ampliﬁed cancer genes (77 genes) (38). Both these re-
sources are literature-based collections of genes whose
mutations and/or ampliﬁcations have been proven to be
causally implicated in tumorigenesis. Among the 444
genes from CGC, 346 are deﬁned as dominant (i.e. het-
erozygous mutations are sufﬁcient to cause tumorigenesis)
and 96 as recessive (i.e. homozygous mutations are
required to initiate tumorigenesis) (37). The second
group is formed of 698 candidate cancer genes from 18
high-throughput mutational screenings (HTMS) on 16
distinct cancer types, such as breast (15,30), colorectal
(30), pancreatic (13–15), lung (10,15), renal (8), prostatic
(15), bladder (12), and ovarian (15) cancers, glioblastoma
(20,21), leukemia (11), lymphoma (23), sarcoma (4),
myeloma (6), medulloblastoma (22), head and neck
squamous cell carcinoma (3,27), and melanoma (29).
These genes represent the subsets of mutated genes that
were identiﬁed as bearing driver mutations, i.e. mutations
that confer growth advantage and are actively involved in
tumor development (31). The third group of cancer genes
contains 457 genes that have been identiﬁed in eleven
whole genome sequencing (WGS) screenings of cancer
genomes, such as breast (26), lung (16,25), prostatic (5),
liver cancer (28), glioblastoma (7), leukemia (17,19),
myeloma (6) and melanoma (24).
Human gene set and orthology information
We gathered information on the human gene set from the
combination of Gencode v.7.0 (39) and RefSeq v. 46 (40).
Gencode is an initiative that aims at identifying and
mapping all human protein coding genes (41). It has
been used as the reference gene set for the Encode
project, for the 1000 Genomes Project and for the design
of the capture baits for whole exome sequencing (39). This
gene set is therefore likely to include all genes present in
current and future mutational screenings of whole cancer
exomes. Starting from 20700 genes in Gencode v.7.0 (cor-
responding to 84408 protein sequences), we removed
multiple isoforms that map to the same gene locus by
aligning all protein sequences to the reference human
genome (hg18) and retaining only the longest isoform
(33). At the end of this pipeline, we were able to
retrieve 19560 unique genes. The 1140 missing genes
corresponded to transcripts that spanned more than
one gene. To recover them, we repeated the same
pipeline with 20750 genes in RefSeq (corresponding to
34571 protein sequences). The union of these two gene
lists led to the ﬁnal dataset of 20531 unique human
genes.
To measure the duplicability of each gene, we identiﬁed
all additional hits on the genome that span at least 60% of
the gene length (33), and found that 4311 human genes
(21% of the total) have at least one additional copy.
Consistently with previous reports (33,34), we found that
cancer genes duplicate signiﬁcantly less than the rest of
human genes (15.7% of the total, p-value=3.010
7,
Pearson’s Chi-squared Test), and dominant genes are
more duplicated than recessive genes (Figure 1A and
Table 1).
We updated the information on orthology relationships
between human and other species to eggNOG v. 2.0 (42).
Orthologs were used to identify the evolutionary origin of
1,466 cancer genes (98% of the total), deﬁned as the
deepest internal node of the tree of life where an
ortholog could be found (34). We conﬁrmed that recessive
cancer genes are mostly ancient genes that have orthologs
in prokaryotes, plants and fungi, while a higher fraction of
Table 1. Primary data correspond to the list of cancer genes as they were extracted from the original papers. Five genes are not present in NCG
3.0 because they could not be mapped to current version of Entrez IDs. Dominant and recessive genes refer to the deﬁnition reported in the
cancer gene census (37). Ancient and recent genes refer to genes that originated between the last universal common ancestor and opisthokonts
and with metazoans or later, respectively. HTMS, high-throughput mutation screening; WGS, whole genome sequencing
Cancer genes Dominant Recessive Ampliﬁed HTMS WGS Total
Primary data 348 98 77 699 457 1,499
Present in NCG 3 346 96 77 698 454 1,494
Duplicated (%) 58 (17.7) 10 (10.5) 23 (29.9) 102 (14.8) 64 (14.3) 230 (15.7)
Ancient (%) 184 (55.6) 63 (66.3) 53 (69.9) 377 (54.6) 273 (61.2) 837 (57.1)
Recent (%) 147 (44.4) 32 (33.7) 24 (31.1) 313 (45.4) 173 (38.8) 629 (42.9)
Hubs (%) 185 (58.6) 71 (75.5) 50 (70.4) 231 (42.6) 116 (34.6) 532 (44.7)
miRNA targets (%) 53 (15.3) 14 (14.6) 17 (22.1) 53 (7.6) 28 (6.2) 118 (7.9)
miRNA hosts (%) 12 (3.5) 6 (6.3) 2 (2.6) 28 (4.0) 17 (3.7) 55 (3.7)
Nucleic Acids Research, 2012,Vol.40, Database issue D979dominant cancer genes appeared with metazoans or later
(Figure 1B and Table 1).
Human interaction network
We rebuilt the human interactome by integrating the latest
releases of ﬁve sources of protein–protein interactions,
such as HPRD (43), BioGRID (44), IntAct (45), MINT
(46) and DIP (47). Only primary interactions were used
while putative interactions inferred from orthology rela-
tionships were discarded. The ﬁnal dataset comprised
98492 binary interactions between 13531 proteins, sup-
ported by 25915 independent publications. The resulting
human interactome contains 13% more proteins and 44%
more interactions than the previous version of NCG, and
reports interaction data for 1189 cancer genes (79% of the
total). We conﬁrmed that cancer genes are enriched in
hubs, deﬁned as top 25% most connected proteins (at
least 15 interactions) (34), and are therefore more con-
nected than the rest of human genes (Figure 1C and
Table 1).
NEW FEATURES OF NCG 3.0
Interactions between cancer gene and miRNAs
miRNAs are endogenous short nucleotide sequences that
interfere with RNA transcripts in the cytoplasm, thus
regulating protein synthesis (48). Alterations in miRNA
expression have been reported during cancer initiation,
progression and metastasis (49). In addition, miRNAs
regulate well-known cancer genes, such as PTEN,
NRAS, KRAS, (48). Because of this involvement in
cancer, we included information about the interactions
between miRNAs and their target cancer genes. Primary
data were extracted from TarBase v.5.0 (50) and
miRecords v.1.0 (51), which collect experimentally sup-
ported interactions between miRNAs and their targets.
The non-redundant integration of the two databases
returned a list of 54 miRNAs that regulate 118 cancer
genes (8% of the total, Table 1). This fraction is signiﬁ-
cantly higher compared to the rest of human genes (4%,
p-value=10
11, Pearson’s Chi-squared Test), and
becomes even higher when only recessive or dominant
Figure 1. Properties of cancer genes. Circles represent the fraction of cancer, dominant, and recessive genes that are (A) singleton or duplicated, (B)
ancient or recent, (C) hubs or non-hubs. Ancient genes originated between the last universal common ancestor and opisthokonts; recent genes
originated with metazoans or later. (D) miRNA targets were derived from TarBase (50) and miRecords (51). Approximately 15% of dominant and
recessive cancer genes are targets of miRNAs, compared with 8% of all cancer genes. (E) Cancer genes were associated to one of the 12 functional
categories based on the corresponding GO terms (34).
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1). This enrichment reﬂects at least partly the fact that
cancer genes are heavily studied and therefore more infor-
mation are available for them compared to other genes. In
addition to miRNA targets, we also retrieved information
on 55 cancer genes that host miRNAs within their
genomic locus (Table 1).
Functional classiﬁcation of cancer genes
To derive the gene functional classiﬁcation, we ﬁrst ex-
tracted 1108 cancer genes (74% of all the total) that
have at least one term at levels 5 and 6 of the biological
process branch of the Gene Ontology (GO) tree (52). We
then grouped all these terms into 12 functional categories,
in order to provide a more general description of the gene
function (34). Dominant and recessive cancer genes have
different functional distributions. In particular, while
dominant genes are mostly involved in the regulation of
transcription, recessive genes are associated with basic
cellular functions such as cell cycle, cell response to
stimuli, cellular and DNA/RNA metabolism (Figure 1E).
Network representation
We developed a novel web interface and added several
new possibilities of querying the database, thus allowing
the user to search for speciﬁc cancer genes, for lists of
genes and miRNAs related to cancer, and for the
presence of cancer genes in genomic regions of interest.
In addition, it is now possible to retrieve the interactions
between a certain miRNA and the cancer genes that are
associated to it, as well as all cancer genes that are miRNA
targets or that host miRNAs within their genomic locus.
Finally, we adopted CytoscapeWeb (53) for the visualiza-
tion of protein–protein and miRNA–target interaction
networks, and for displaying the evolutionary origin of
cancer genes and their orthologs in other species.
IDENTIFICATION OF CANDIDATE CANCER GENES
USING NCG
In addition to providing a comprehensive description of
the properties of cancer genes, NCG can be used to
identify new possible candidates, based on the hypothesis
that genes with systems-level properties similar to known
cancer genes may also play similar roles in cancer (36).
Following this idea, two almost identical paralogs,
GNAQ GNA11, have recently been associated to the
same tumor type (54). Here, we hypothesize that a
similar association can be drawn for DNMT3A and its
paralog DNMT3B. Both these methyltransferases cause
Figure 2. Functional redundancy of DNMT3A and DNMT3B. (A) Protein-protein interaction network of DNMT3A and DNMT3B. The two
proteins share 14 interactors, which are mostly involved in the epigenetic control of chromatin and in the regulation of gene expression. Primary
interactions are physical interactions of a protein directly with DNMT3A or DNMT3B, while secondary interactions are physical interactions
between their primary interactors. (B) Interaction network between DNMT3A and DNMT3B and target miRNAs. Both genes are regulated by
members of the miR-29 family, whose expression is altered in cancer and is inversely correlated with the gene expression (57). CGC, cancer gene
census; HTMS, high-throughput mutational screenings; WGS, whole genome sequencing.
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poietic cells and are involved in hematopoietic stem-cell
renewal (55). DNMT3A is an already known cancer gene,
part of the cancer gene census and frequently mutated in
leukemia (56). Although its role in tumorigenesis is still
unclear, it has been hypothesized that mutations in
DNMT3A either induce altered gene expression or affect
genome stability (56). To date there is no evidence that
also DNMT3B is mutated in cancer, although NCG 3.0
provides several indications that this might be indeed the
case. First, both DNMT3A and DNMT3B originated with
eukaryotes and are associated with the same GO terms,
thus indicating functional redundancy. Second, the
encoded proteins DNMT3A and DNMT3B share 14
interactors, which, in turn, are connected through second-
ary interactions (Figure 2A). The resulting highly inter-
connected module involves key players in epigenetic
changes of chromatin, and consequent regulation of
gene expression. Third, both genes are targets of three
miRNAs of the miR-29 family (Figure 2B). The
downregulation of these miRNAs induces aberrant ex-
pression of both DNMT3A and DNMT3B in
non-small-cell lung cancer (57) and the upregulation of
both paralogs has been observed in several tumor types
(58). We hypothesize that the aberrant expression can be
related to the acquisition of mutations in the sequence of
these genes.
ACKNOWLEDGMENTS
The authors thank all members of the Ciccarelli lab for
testing NCG and providing useful suggestion to improve
it.
FUNDING
Funding for open access charge: Associazione Italiana
Ricerca sul Cancro (AIRC) and Fondazione Cariplo (to
F.D.C.).
REFERENCES
1. von Hansemann,D.P. (1890) On primary cancer of the liver.
Berl. klin. Wschr., 27, 353–356.
2. Boveri,T. (1914) Zur Frage der Entstehung Maligner Tumoren.
Jena: Gustav Fischer, 1, 1–64.
3. Agrawal,N., Frederick,M.J., Pickering,C.R., Bettegowda,C.,
Chang,K., Li,R.J., Fakhry,C., Xie,T.X., Zhang,J., Wang,J. et al.
(2011) Exome sequencing of head and neck squamous cell
carcinoma reveals inactivating mutations in NOTCH1. Science,
333, 1154–1157.
4. Barretina,J., Taylor,B.S., Banerji,S., Ramos,A.H., Lagos-
Quintana,M., Decarolis,P.L., Shah,K., Socci,N.D., Weir,B.A.,
Ho,A. et al. (2010) Subtype-speciﬁc genomic alterations deﬁne
new targets for soft-tissue sarcoma therapy. Nat. Genet., 42,
715–721.
5. Berger,M.F., Lawrence,M.S., Demichelis,F., Drier,Y.,
Cibulskis,K., Sivachenko,A.Y., Sboner,A., Esgueva,R.,
Pﬂueger,D., Sougnez,C. et al. (2011) The genomic complexity of
primary human prostate cancer. Nature, 470, 214–220.
6. Chapman,M.A., Lawrence,M.S., Keats,J.J., Cibulskis,K.,
Sougnez,C., Schinzel,A.C., Harview,C.L., Brunet,J.P.,
Ahmann,G.J., Adli,M. et al. (2011) Initial genome sequencing and
analysis of multiple myeloma. Nature, 471, 467–472.
7. Clark,M.J., Homer,N., O’Connor,B.D., Chen,Z., Eskin,A.,
Lee,H., Merriman,B. and Nelson,S.F. (2010) U87MG decoded:
the genomic sequence of a cytogenetically aberrant human cancer
cell line. PLoS Genet., 6, e1000832.
8. Dalgliesh,G.L., Furge,K., Greenman,C., Chen,L., Bignell,G.,
Butler,A., Davies,H., Edkins,S., Hardy,C., Latimer,C. et al. (2010)
Systematic sequencing of renal carcinoma reveals inactivation of
histone modifying genes. Nature, 463, 360–363.
9. Ding,L., Ellis,M.J., Li,S., Larson,D.E., Chen,K., Wallis,J.W.,
Harris,C.C., McLellan,M.D., Fulton,R.S., Fulton,L.L. et al.
(2010) Genome remodelling in a basal-like breast cancer
metastasis and xenograft. Nature, 464, 999–1005.
10. Ding,L., Getz,G., Wheeler,D.A., Mardis,E.R., McLellan,M.D.,
Cibulskis,K., Sougnez,C., Greulich,H., Muzny,D.M.,
Morgan,M.B. et al. (2008) Somatic mutations affect key pathways
in lung adenocarcinoma. Nature, 455, 1069–1075.
11. Greif,P.A., Eck,S.H., Konstandin,N.P., Benet-Pages,A.,
Ksienzyk,B., Dufour,A., Vetter,A.T., Popp,H.D., Lorenz-
Depiereux,B., Meitinger,T. et al. (2011) Identiﬁcation of recurring
tumor-speciﬁc somatic mutations in acute myeloid leukemia by
transcriptome sequencing. Leukemia, 25, 821–827.
12. Gui,Y., Guo,G., Huang,Y., Hu,X., Tang,A., Gao,S., Wu,R.,
Chen,C., Li,X., Zhou,L. et al. (2011) Frequent mutations of
chromatin remodeling genes in transitional cell carcinoma of the
bladder. Nat. Genet., 43, 875–878.
13. Jiao,Y., Shi,C., Edil,B.H., de Wilde,R.F., Klimstra,D.S.,
Maitra,A., Schulick,R.D., Tang,L.H., Wolfgang,C.L., Choti,M.A.
et al. (2011) DAXX/ATRX, MEN1, and mTOR pathway genes
are frequently altered in pancreatic neuroendocrine tumors.
Science, 331, 1199–1203.
14. Jones,S., Zhang,X., Parsons,D.W., Lin,J.C., Leary,R.J.,
Angenendt,P., Mankoo,P., Carter,H., Kamiyama,H., Jimeno,A.
et al. (2008) Core signaling pathways in human pancreatic cancers
revealed by global genomic analyses. Science, 321, 1801–1806.
15. Kan,Z., Jaiswal,B.S., Stinson,J., Janakiraman,V., Bhatt,D.,
Stern,H.M., Yue,P., Haverty,P.M., Bourgon,R., Zheng,J. et al.
(2010) Diverse somatic mutation patterns and pathway alterations
in human cancers. Nature, 466, 869–873.
16. Lee,W., Jiang,Z., Liu,J., Haverty,P.M., Guan,Y., Stinson,J.,
Yue,P., Zhang,Y., Pant,K.P., Bhatt,D. et al. (2010) The mutation
spectrum revealed by paired genome sequences from a lung
cancer patient. Nature, 465, 473–477.
17. Ley,T.J., Mardis,E.R., Ding,L., Fulton,B., McLellan,M.D.,
Chen,K., Dooling,D., Dunford-Shore,B.H., McGrath,S.,
Hickenbotham,M. et al. (2008) DNA sequencing of a
cytogenetically normal acute myeloid leukaemia genome. Nature,
456, 66–72.
18. Li,M., Zhao,H., Zhang,X., Wood,L.D., Anders,R.A., Choti,M.A.,
Pawlik,T.M., Daniel,H.D., Kannangai,R., Offerhaus,G.J. et al.
(2011) Inactivating mutations of the chromatin remodeling gene
ARID2 in hepatocellular carcinoma. Nat. Genet., 43, 828–829.
19. Mardis,E.R., Ding,L., Dooling,D.J., Larson,D.E., McLellan,M.D.,
Chen,K., Koboldt,D.C., Fulton,R.S., Delehaunty,K.D.,
McGrath,S.D. et al. (2009) Recurring mutations found by
sequencing an acute myeloid leukemia genome. N. Engl. J. Med.,
361, 1058–1066.
20. McLendon,R., Friedman,A., Bigner,D., Van,M.E.G., Brat,D.,
Mastrogianakis,G., Olson,J., Mikkelsen,T., Lehman,N., Aldape,K.
et al. (2008) Comprehensive genomic characterization deﬁnes
human glioblastoma genes and core pathways. Nature, 455,
1061–1068.
21. Parsons,D.W., Jones,S., Zhang,X., Lin,J.C., Leary,R.J.,
Angenendt,P., Mankoo,P., Carter,H., Siu,I.M., Gallia,G.L. et al.
(2008) An integrated genomic analysis of human glioblastoma
multiforme. Science, 321, 1807–1812.
22. Parsons,D.W., Li,M., Zhang,X., Jones,S., Leary,R.J., Lin,J.C.,
Boca,S.M., Carter,H., Samayoa,J., Bettegowda,C. et al. (2010)
The genetic landscape of the childhood cancer medulloblastoma.
Science, 331, 435–439.
23. Pasqualucci,L., Trifonov,V., Fabbri,G., Ma,J., Rossi,D.,
Chiarenza,A., Wells,V.A., Grunn,A., Messina,M., Elliot,O. et al.
(2011) Analysis of the coding genome of diffuse large B-cell
lymphoma. Nat. Genet.
D982 Nucleic AcidsResearch, 2012, Vol.40,Database issue24. Pleasance,E.D., Cheetham,R.K., Stephens,P.J., McBride,D.J.,
Humphray,S.J., Greenman,C.D., Varela,I., Lin,M.L.,
Ordonez,G.R., Bignell,G.R. et al. (2010) A comprehensive
catalogue of somatic mutations from a human cancer genome.
Nature, 463, 191–196.
25. Pleasance,E.D., Stephens,P.J., O’Meara,S., McBride,D.J.,
Meynert,A., Jones,D., Lin,M.L., Beare,D., Lau,K.W.,
Greenman,C. et al. (2010) A small-cell lung cancer genome with
complex signatures of tobacco exposure. Nature, 463, 184–190.
26. Shah,S.P., Morin,R.D., Khattra,J., Prentice,L., Pugh,T.,
Burleigh,A., Delaney,A., Gelmon,K., Guliany,R., Senz,J. et al.
(2009) Mutational evolution in a lobular breast tumour proﬁled
at single nucleotide resolution. Nature, 461, 809–813.
27. Stransky,N., Egloff,A.M., Tward,A.D., Kostic,A.D., Cibulskis,K.,
Sivachenko,A., Kryukov,G.V., Lawrence,M., Sougnez,C.,
McKenna,A. et al. (2011) The mutational landscape of head and
neck squamous cell carcinoma. Science, 333, 1157–1160.
28. Totoki,Y., Tatsuno,K., Yamamoto,S., Arai,Y., Hosoda,F.,
Ishikawa,S., Tsutsumi,S., Sonoda,K., Totsuka,H., Shirakihara,T.
et al. (2011) High resolution characterization of a hepatocellular
carcinoma genome. Nat. Genet., 43, 464–469.
29. Wei,X., Walia,V., Lin,J.C., Teer,J.K., Prickett,T.D., Gartner,J.,
Davis,S., Stemke-Hale,K., Davies,M.A., Gershenwald,J.E. et al.
(2011) Exome sequencing identiﬁes GRIN2A as frequently
mutated in melanoma. Nat. Genet., 43, 442–446.
30. Wood,L.D., Parsons,D.W., Jones,S., Lin,J., Sjoblom,T.,
Leary,R.J., Shen,D., Boca,S.M., Barber,T., Ptak,J. et al. (2007)
The genomic landscapes of human breast and colorectal cancers.
Science, 318, 1108–1113.
31. Stratton,M.R., Campbell,P.J. and Futreal,P.A. (2009) The cancer
genome. Nature, 458, 719–724.
32. Ciccarelli,F.D. (2010) The (r)evolution of cancer genetics. BMC
Biol., 8, 74.
33. Rambaldi,D., Giorgi,F.M., Capuani,F., Ciliberto,A. and
Ciccarelli,F.D. (2008) Low duplicability and network fragility of
cancer genes. Trends Genet., 24, 427–430.
34. D’Antonio,M. and Ciccarelli,F.D. (2011) Modiﬁcation of gene
duplicability during the evolution of protein interaction network.
PLoS Comput. Biol., 7, e1002029.
35. Syed,A.S., D’Antonio,M. and Ciccarelli,F.D. (2010) Network of
cancer genes: a web resource to analyze duplicability, orthology
and network properties of cancer genes. Nucleic Acids Res., 38,
D670–D675.
36. Anelli,V., Santoriello,C., Distel,M., Koster,R.W., Ciccarelli,F.D.
and Mione,M. (2009) Global repression of cancer gene expression
in a zebraﬁsh model of melanoma is linked to epigenetic
regulation. Zebraﬁsh, 6, 417–424.
37. Futreal,P.A., Coin,L., Marshall,M., Down,T., Hubbard,T.,
Wooster,R., Rahman,N. and Stratton,M.R. (2004) A census of
human cancer genes. Nat. Rev. Cancer, 4, 177–183.
38. Santarius,T., Shipley,J., Brewer,D., Stratton,M.R. and
Cooper,C.S. (2010) A census of ampliﬁed and overexpressed
human cancer genes. Nat. Rev. Cancer, 10, 59–64.
39. Coffey,A.J., Kokocinski,F., Calafato,M.S., Scott,C.E., Palta,P.,
Drury,E., Joyce,C.J., Leproust,E.M., Harrow,J., Hunt,S. et al.
(2011) The GENCODE exome: sequencing the complete
human exome. Eur. J. Hum. Genet., 19, 827–831.
40. Pruitt,K.D., Tatusova,T. and Maglott,D.R. (2007) NCBI
reference sequences (RefSeq): a curated non-redundant sequence
database of genomes, transcripts and proteins. Nucleic Acids Res.,
35, D61–D65.
41. Harrow,J., Denoeud,F., Frankish,A., Reymond,A., Chen,C.K.,
Chrast,J., Lagarde,J., Gilbert,J.G., Storey,R., Swarbreck,D. et al.
(2006) GENCODE: producing a reference annotation for
ENCODE. Genome Biol., 7(Suppl. 1), S41–S49.
42. Muller,J., Szklarczyk,D., Julien,P., Letunic,I., Roth,A., Kuhn,M.,
Powell,S., von Mering,C., Doerks,T., Jensen,L.J. et al. (2010)
eggNOG v2.0: extending the evolutionary genealogy of genes with
enhanced non-supervised orthologous groups, species and
functional annotations. Nucleic Acids Res., 38, D190–D195.
43. Keshava Prasad,T.S., Goel,R., Kandasamy,K., Keerthikumar,S.,
Kumar,S., Mathivanan,S., Telikicherla,D., Raju,R., Shafreen,B.,
Venugopal,A. et al. (2009) Human protein reference database–
2009 update. Nucleic Acids Res., 37, D767–D772.
44. Stark,C., Breitkreutz,B.J., Chatr-Aryamontri,A., Boucher,L.,
Oughtred,R., Livstone,M.S., Nixon,J., Van Auken,K., Wang,X.,
Shi,X. et al. (2010) The BioGRID interaction database: 2011
update. Nucleic Acids Res., 39, D698–D704.
45. Aranda,B., Achuthan,P., Alam-Faruque,Y., Armean,I., Bridge,A.,
Derow,C., Feuermann,M., Ghanbarian,A.T., Kerrien,S.,
Khadake,J. et al. (2009) The IntAct molecular interaction
database in 2010. Nucleic Acids Res., 38, D525–D531.
46. Ceol,A., Chatr Aryamontri,A., Licata,L., Peluso,D., Briganti,L.,
Perfetto,L., Castagnoli,L. and Cesareni,G. (2009) MINT, the
molecular interaction database: 2009 update. Nucleic Acids Res.,
38, D532–D539.
47. Salwinski,L., Miller,C.S., Smith,A.J., Pettit,F.K., Bowie,J.U. and
Eisenberg,D. (2004) The database of interacting proteins: 2004
update. Nucleic Acids Res., 32, D449–D451.
48. Inui,M., Martello,G. and Piccolo,S. (2010) MicroRNA control of
signal transduction. Nat. Rev. Mol. Cell. Biol., 11, 252–263.
49. Croce,C.M. (2009) Causes and consequences of microRNA
dysregulation in cancer. Nat. Rev. Genet., 10, 704–714.
50. Papadopoulos,G.L., Reczko,M., Simossis,V.A., Sethupathy,P. and
Hatzigeorgiou,A.G. (2009) The database of experimentally
supported targets: a functional update of TarBase.
Nucleic Acids Res., 37, D155–D158.
51. Xiao,F., Zuo,Z., Cai,G., Kang,S., Gao,X. and Li,T. (2009)
miRecords: an integrated resource for microRNA-target
interactions. Nucleic Acids Res., 37, D105–D110.
52. Ashburner,M., Ball,C.A., Blake,J.A., Botstein,D., Butler,H.,
Cherry,J.M., Davis,A.P., Dolinski,K., Dwight,S.S., Eppig,J.T.
et al. (2000) Gene ontology: tool for the uniﬁcation of biology.
The Gene Ontology Consortium. Nat. Genet., 25, 25–29.
53. Lopes,C.T., Franz,M., Kazi,F., Donaldson,S.L., Morris,Q. and
Bader,G.D. (2010) Cytoscape Web: an interactive web-based
network browser. Bioinformatics, 26, 2347–2348.
54. Van Raamsdonk,C.D., Griewank,K.G., Crosby,M.B.,
Garrido,M.C., Vemula,S., Wiesner,T., Obenauf,A.C.,
Wackernagel,W., Green,G., Bouvier,N. et al. (2010) Mutations in
GNA11 in uveal melanoma. N. Engl. J. Med., 363, 2191–2199.
55. Tadokoro,Y., Ema,H., Okano,M., Li,E. and Nakauchi,H. (2007)
De novo DNA methyltransferase is essential for self-renewal,
but not for differentiation, in hematopoietic stem cells.
J. Exp. Med., 204, 715–722.
56. Ley,T.J., Ding,L., Walter,M.J., McLellan,M.D., Lamprecht,T.,
Larson,D.E., Kandoth,C., Payton,J.E., Baty,J., Welch,J. et al.
(2010) DNMT3A mutations in acute myeloid leukemia.
N. Engl. J. Med., 363, 2424–2433.
57. Fabbri,M., Garzon,R., Cimmino,A., Liu,Z., Zanesi,N.,
Callegari,E., Liu,S., Alder,H., Costinean,S., Fernandez-
Cymering,C. et al. (2007) MicroRNA-29 family reverts aberrant
methylation in lung cancer by targeting DNA methyltransferases
3A and 3B. Proc. Natl Acad. Sci. USA, 104, 15805–15810.
58. Li,B., Wang,B., Niu,L.J., Jiang,L. and Qiu,C.C. (2011)
Hypermethylation of multiple tumor-related genes associated
with DNMT3b up-regulation served as a biomarker for early
diagnosis of esophageal squamous cell carcinoma. Epigenetics, 6,
307–316.
Nucleic Acids Research, 2012,Vol.40, Database issue D983